Hypertonic Saline Dextran (HSD) and Intraosseous Vascular Access for the Treatment of Haemorrhagic Hypotension in the Far-forward Combat Arena

M. A. Dubick, George Kramer

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Battlefield statistics show that 50% of deaths are due to acute haemorrhage. Hypertonic (7.5% saline)/hyperoncotic (6% Dextran-70) solution (HSD) for the treatment of haemorrhagic hypotension may have physiologic and logistic advantages over conventional fluid therapy for use in the far-forward combat arena. HSD rapidly expands plasma volume and stabilizes haemodynamic variables in various animal models of haemorrhage, at a volume dose of about 1/10 of conventional lactated Ringers solution. However, combat conditions, as well as the physiological status of the patient may result in time delays or failure to achieve vascular access. Over the past 5 years we have investigated intraosseous infusion of HSD via the sternum or tibia, as a possible means of achieving rapid vascular access and plasma volume expansion. These data in experimental animals and one clinical study show that HSD can be safely and rapidly infused via the intraosseous route achieving the same haemodynamic benefit as observed with intravenous administration.

Original languageEnglish (US)
Pages (from-to)64-69
Number of pages6
JournalAnnals of the Academy of Medicine Singapore
Volume26
Issue number1
StatePublished - Jan 1997

Fingerprint

dextran - saline drug combination
Hypotension
Blood Vessels
Plasma Volume
Intraosseous Infusions
Hemodynamics
Hemorrhage
Sternum
Fluid Therapy
Dextrans
Tibia
Intravenous Administration
Therapeutics
Animal Models

Keywords

  • Experimental animals
  • Human
  • Resuscitation

ASJC Scopus subject areas

  • Medicine(all)

Cite this

@article{fe426327763f48b9a5c15057ab2fe7d5,
title = "Hypertonic Saline Dextran (HSD) and Intraosseous Vascular Access for the Treatment of Haemorrhagic Hypotension in the Far-forward Combat Arena",
abstract = "Battlefield statistics show that 50{\%} of deaths are due to acute haemorrhage. Hypertonic (7.5{\%} saline)/hyperoncotic (6{\%} Dextran-70) solution (HSD) for the treatment of haemorrhagic hypotension may have physiologic and logistic advantages over conventional fluid therapy for use in the far-forward combat arena. HSD rapidly expands plasma volume and stabilizes haemodynamic variables in various animal models of haemorrhage, at a volume dose of about 1/10 of conventional lactated Ringers solution. However, combat conditions, as well as the physiological status of the patient may result in time delays or failure to achieve vascular access. Over the past 5 years we have investigated intraosseous infusion of HSD via the sternum or tibia, as a possible means of achieving rapid vascular access and plasma volume expansion. These data in experimental animals and one clinical study show that HSD can be safely and rapidly infused via the intraosseous route achieving the same haemodynamic benefit as observed with intravenous administration.",
keywords = "Experimental animals, Human, Resuscitation",
author = "Dubick, {M. A.} and George Kramer",
year = "1997",
month = "1",
language = "English (US)",
volume = "26",
pages = "64--69",
journal = "Annals of the Academy of Medicine, Singapore",
issn = "0304-4602",
publisher = "Academy of Medicine Singapore",
number = "1",

}

TY - JOUR

T1 - Hypertonic Saline Dextran (HSD) and Intraosseous Vascular Access for the Treatment of Haemorrhagic Hypotension in the Far-forward Combat Arena

AU - Dubick, M. A.

AU - Kramer, George

PY - 1997/1

Y1 - 1997/1

N2 - Battlefield statistics show that 50% of deaths are due to acute haemorrhage. Hypertonic (7.5% saline)/hyperoncotic (6% Dextran-70) solution (HSD) for the treatment of haemorrhagic hypotension may have physiologic and logistic advantages over conventional fluid therapy for use in the far-forward combat arena. HSD rapidly expands plasma volume and stabilizes haemodynamic variables in various animal models of haemorrhage, at a volume dose of about 1/10 of conventional lactated Ringers solution. However, combat conditions, as well as the physiological status of the patient may result in time delays or failure to achieve vascular access. Over the past 5 years we have investigated intraosseous infusion of HSD via the sternum or tibia, as a possible means of achieving rapid vascular access and plasma volume expansion. These data in experimental animals and one clinical study show that HSD can be safely and rapidly infused via the intraosseous route achieving the same haemodynamic benefit as observed with intravenous administration.

AB - Battlefield statistics show that 50% of deaths are due to acute haemorrhage. Hypertonic (7.5% saline)/hyperoncotic (6% Dextran-70) solution (HSD) for the treatment of haemorrhagic hypotension may have physiologic and logistic advantages over conventional fluid therapy for use in the far-forward combat arena. HSD rapidly expands plasma volume and stabilizes haemodynamic variables in various animal models of haemorrhage, at a volume dose of about 1/10 of conventional lactated Ringers solution. However, combat conditions, as well as the physiological status of the patient may result in time delays or failure to achieve vascular access. Over the past 5 years we have investigated intraosseous infusion of HSD via the sternum or tibia, as a possible means of achieving rapid vascular access and plasma volume expansion. These data in experimental animals and one clinical study show that HSD can be safely and rapidly infused via the intraosseous route achieving the same haemodynamic benefit as observed with intravenous administration.

KW - Experimental animals

KW - Human

KW - Resuscitation

UR - http://www.scopus.com/inward/record.url?scp=0030630225&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030630225&partnerID=8YFLogxK

M3 - Article

VL - 26

SP - 64

EP - 69

JO - Annals of the Academy of Medicine, Singapore

JF - Annals of the Academy of Medicine, Singapore

SN - 0304-4602

IS - 1

ER -